SuperworthTwist Bioscience profit margin TWST
Gross, operating and net profit as a share of revenue over the last twelve months, from 2022.
- Net margin, 12 months
- −31.7%
- Operating margin, 12 months
- −33.6%
- Net margin on a year earlier
- −8.1 pts
- Peer median
- 26.3%
Over the twelve months to Jun 30, 2026, Twist Bioscience kept −31.7% of its revenue as net profit, with an operating margin of −33.6% and a gross margin of 52.0%.
The median for 10 biotech stocks of a similar size is 26.3%.
Profit margin over time
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2025 | −20.6% | −36.2% | 50.7% |
| FY2024 | −66.7% | −70.6% | 42.6% |
| FY2023 | −83.5% | −88.6% | 36.6% |
| FY2022 | n/a | n/a | 41.4% |
| FY2021 | n/a | n/a | 39.1% |
| FY2020 | n/a | n/a | 31.8% |
| FY2019 | n/a | n/a | 12.8% |
| FY2018 | n/a | n/a | −26.6% |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q3 FY26 | −31.7% | −8.1 pts | −33.6% | |
| Q2 FY26 | −19.8% | +35.1 pts | −33.9% | |
| Q1 FY26 | −19.6% | +40.2 pts | −34.4% | |
| Q4 FY25 | −20.6% | +46.1 pts | −36.2% | |
| Q3 FY25 | −23.5% | +51.1 pts | −39.3% | |
| Q2 FY25 | −55.0% | +14.3 pts | −57.9% | |
| Q1 FY25 | −59.8% | +18.7 pts | −63.1% | |
| Q4 FY24 | −66.7% | +16.8 pts | −70.6% | |
| Q3 FY24 | −74.6% | +14.3 pts | −79.6% | |
| Q2 FY24 | −69.2% | +24.1 pts | −74.5% | |
| Q1 FY24 | −78.4% | +20.8 pts | −83.7% | |
| Q4 FY23 | −83.5% | n/a | −88.6% |
Against its peers
Companies in Biotechnology nearest Twist Bioscience's size, closest first, today.
| Company | Profit margin |
|---|---|
| TWSTTwist Bioscience | −31.7% |
| KRYSKrystal Biotech | 54.8% |
| RGENRepligen | 5.3% |
| TECHBIO-TECHNE | 15.0% |
| HALOHalozyme Therapeutics | 24.9% |
| NBIXNeurocrine Biosciences | 20.9% |
| EXELExelixis | 35.3% |
| INCYIncyte | 27.7% |
| UTHRUnited Therapeutics | 41.6% |
| ALNYAlnylam Pharmaceuticals | 16.8% |
| ADMAAdma Biologics | 33.0% |
| Peer median | 26.3% |
Where Twist Bioscience ranks
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on Twist Bioscience
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.